

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-39 (cancelled).

40 (currently amended). A disease associated, antigen activated ~~continuous~~ cytotoxic T-cell line ~~obtained by a method according to claim 1, wherein the cells have exceeded or have an expected life-span of at least 40 PD.~~

41-59 (cancelled).

60 (new). A T-cell line according to claim 40 wherein the functional profile of the cytotoxic T cells essentially corresponds to the functional profile of the initial cytotoxic T cells of the tissue sample.

61 (new). A T-cell line according to claim 40 obtained by culturing a tissue sample from a human patient comprising normal disease associated antigen activated cytotoxic T-cells in the presence of at least two factors which promote T-cell growth and one or more additional compounds promoting cytotoxic T cell selection and expansion exceeding 40 PD.

62 (new). A T-cell line according to claim 61, wherein the factors which promote cytotoxic T-cell growth are selected from the group consisting of cytokines which promote cytotoxic T-cell growth..

63 (new). A T-cell line according to claim 62, wherein the cytokines are selected from the group consisting of IL-2, IL-4, IL-7, IL-9, IL-10, IL-15, IL-16 and functionally similar cytokines.

64 (new). A T-cell line according to claim 63, wherein a combination of at least one of IL-2 or IL-15; and at least one

of IL-4 or IL-7 or IL-9 is used.

65 (new). A T-cell line according to claim 64, wherein a combination of IL-2 and IL-4 is used.

66 (new). A T-cell line according to claim 62, wherein each of the cytokines is used in a concentration of at least 1 nM.

67 (new). A T-cell line according to claim 66, wherein each of the cytokines is used in a concentration of at least 2.5 nM.

68 (new). A T-cell line according to claim 61, wherein the tissue sample is selected from the group consisting of a biopsy, sputum, a swab, a gastric lavage, a bronchial lavage, an intestinal lavage, or another body fluid.

69 (new). A T-cell line according to claim 68, wherein the tissue sample is a body fluid selected from the group consisting of spinal, pleural, pericardial, synovial, blood and bone marrow body fluids.

70 (new). A T-cell line according to claim 60, wherein the cytotoxic T-cells are cells having a CD8+ phenotype.

71 (new). A T-cell line according to claim 60, wherein the cytotoxic T-cells are tumour infiltrating lymphocytes (TIL) or cells having similar properties.

72 (new). A cytotoxic T-cell line according to claim 61, wherein the one or more additional compounds are selected from GM-CSF, caspase inhibitors, Z-VAD, α -CD95, IL-10, IL-12, IL-16, and functionally similar compounds.

73 (new). A cytotoxic T-cell line according to claim 60, wherein the disease is of neoplastic origin.

74 (new). A cytotoxic T-cell line according to claim 73, wherein the disease is selected from the group consisting of malignant melanoma, renal carcinoma, breast cancer, lung cancer, cancer of the uterus, prostatic cancer, hepatic carcinoma, and cutaneous lymphoma.

75 (new). An immunological composition comprising disease associated antigen activated cytotoxic T-cells isolated from the cytotoxic T-cell line according to claim 40.

76 (new). An immunological composition according to claim 75, wherein the T-cells are reactivated in the presence of one or more reactivating antigens.

77 (new). An immunological composition according to claim 76, wherein each reactivating antigen or antigen is selected from the group consisting of disease associated antigens, alloantigens and super-antigens.

78 (new). An immunological composition according to claim 17, wherein each reactivating antigen is a superantigen selected from the group consisting of SEA, SEB, SEC, SED, SEE, TSST, Streptococcus pyogenes enterotoxin A, B and C, and Mycoplasma arthritidis antigen.

79 (new). An immunological composition according to claim 75, wherein the T-cells are incapable of further cell division.

80 (new). A method of obtaining a cytotoxic T-cell line according to claim 40 comprising

- (a) obtaining a tissue sample comprising disease associated, antigen activated cytotoxic T cells from a human patient, and
- (b) culturing said tissue sample in the presence of at least two factors which promote T-cell growth and one or more additional compounds promoting cytotoxic T-cell selection and expansion exceeding 40 PD.

81 (new). A method according to claim 80 wherein the functional profile of the cytotoxic T-cells essentially correspond to the initial functional profile of the cytotoxic T-cells of the tissue sample.

82 (new). A method for treatment of neoplastic diseases

comprising administering an immunological composition comprising an immunologically effective amount of disease associated antigen activated cytotoxic T-cells isolated from the continuous T-cell line according to claim 40.

83 (new). A method according to claim 82 wherein the functional profile of the cytotoxic T-cells essentially corresponds to the initial functional profile of the cytotoxic T-cells of the tissues sample.

84 (new). A cell line according to claim 40 wherein the cells have exceeded 40 PD.

85 (new). A cell line according to claim 40 wherein the expected life-span is at least 60 PD.

86 (new). A cell line according to claim 40 wherein the expected life-span is at least 100 PD.

87 (new). A cell line according to claim 40 wherein the expected life-span is at least 150 PD.

88 (new). A cell line according to claim 40 wherein the expected life-span is at least 200 PD.